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Abstract
Background: Safe and effective insulin therapy for diabetes mellitus requires initial dose titration and regular
adjustments based on blood glucose (BG) monitoring. Our objective was to explore the use of BG measurement in
phase-III clinical studies of insulin analogs. These studies provide safety and efficacy information for regulatory
authorities and are the basis for insulin analog regulatory approval.
Methods: A systematic review of phase-III studies of rapid-acting insulin analogs (insulin lispro, insulin aspart and
insulin glulisine) and pre-mixed insulin analogs (biphasic insulin aspart and insulin lispro mix) was conducted.
Studies were identified using manufacturers’ databases. Search for reports was performed in Medline and registry of
clinical trials (clinicaltrials.gov). The European Medicines Agency was contacted to provide Clinical Study Reports.
Results: Forty-five studies were included. Regular BG measurements were reported in 100 % of the studies and
were performed by either self-monitoring of blood glucose (SMBG) alone in 84 %, laboratory alone in 7 %, and
both SMBG and laboratory in 9 % of studies. In total, 93 % of the studies reported SMBG. Most studies (91 %)
reported insulin therapy adjustments based on BG measurements.
Conclusions: The findings suggest that BG monitoring and specifically SMBG are co-dependent technologies with
insulin analogs. BG measurement is used in most phase-III registration studies for establishing safe and efficacious
insulin administration and is recommended in the insulin labels. The indispensable role of SMBG in treatment of
insulin-dependent patients should receive attention from health care payers to assess and reimburse SMBG along
with insulin to avoid adverse events from inappropriate insulin administration and associated costs.
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Background
Multiple stakeholders, including regulatory authorities,
clinicians, payers (commissioners) and health technology
assessors, are involved in market introduction and
management pathways for health technologies. From the
perspective of these stakeholders, monitoring of blood
glucose (BG) in insulin-dependent diabetes has strong glo-
bal support from clinical societies [1–6]. The American
Diabetes Association guidelines specify that “major clinical
trials of insulin-treated patients that demonstrated the
benefits of intensive glycemic control on diabetes compli-
cations have included self-monitoring of blood glucose
(SMBG) as part of multifactorial interventions, suggesting
that SMBG is a component of effective therapy” [1].
Regulatory authorities have approved the use of blood
glucose meters for use with insulin products and have
outlined instructions for the measurement of BG [7].
Health technology assessments, although rarely focused
on SMBG in insulin-dependent diabetes, have also been in
general supportive of BG monitoring [8,9]. Lack of under-
standing of the role of BG monitoring in the safe and
effective use of insulin leads to restrictions or no coverage
of SMBG in some developing countries, while reimburse-
ment for insulin treatment is provided [10]. According to
Czupryniak et al. [11], access to SMBG is limited
especially in Central and Eastern European countries. In a
survey conducted in 47 countries by the International
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Diabetes Federation, existing limitations for access to
SMBG were also confirmed [12]. Limitations usually do
not have rational ground and can mainly be explained by
the absence of a consistent reimbursement system. An-
other potential reason for restrictions of SMBG is the lack
of randomized controlled trials (RCTs) for comparing the
management of insulin-dependent diabetes with and
without SMBG. RCTs are considered as a “gold standard”
for assessment of safety and efficacy of health care
interventions [13], although their role in assessment of
effectiveness of SMBG as stand-alone technology can be
reasonably questioned. The role of SMBG in insulin-
dependent diabetes has not been studied in RCTs and
does not require validation in comparative studies, as it
would be considered unethical to allocate patients to insu-
lin without the ability to determine and adjust dose based
on BG measurements. Another contributing factor to
complexity of assessment of efficacy of SMBG is that is it
a diagnostic measure, not a treatment intervention.
SMBG and the use of insulin are ultimately linked
together for an effective and safe therapy. Regulatory
approval of insulin has been established in phase III
clinical studies [14]. Because BG is an essential compo-
nent of these foundational studies of the safety and
efficacy of insulin treatment, it provides additional
arguments for the use of SMBG, and thus confirms the
co-dependent nature of SMBG and insulin treatment.
Therefore, it is necessary to consider them jointly in
evidence evaluations and reimbursement decision
making, and BG monitoring should be mentioned as a
part of the intervention in the studies on insulin analogs.
In a preliminary review of phase III clinical studies of
insulin analogs, it was found that in only 12 of the 57
study synopses analyzed, dose adjustments were made
according to BG measurements [7]. In addition, full text
reports were not available for review in most of the
studies. Our study aimed to explore this area further,
and we hypothesized that phase III registration studies
of commonly used insulin analogs (biphasic insulin
aspart, insulin aspart, insulin glulisine, insulin lispro and
insulin lispro mix) include BG monitoring and conse-
quent regular dose adjustment as an essential element of
the research protocol. The resulting impact on the
treatment outcomes is thought to be a joint effect of the
co-dependent technologies.
Methods
A systematic literature review was performed in multiple
steps. First, a systematic search for phase III clinical
studies was performed on the manufacturers’ websites
(Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A.).
The rapid-acting insulin analogs included insulin aspart
(NovoRapid®), insulin glulisine (Apidra®) and insulin
lispro (Humalog®). Pre-mixed insulin analogs included
biphasic insulin aspart (Novo Mix®) and insulin lispro
mix (Humalog Mix®). All searches were conducted in
December 2013. Second, Clinical Study Reports were
requested from the European Medicines Agency (EMA),
according to Regulation (EC) No 1049/2001. Third, an
additional search for full-text publications was per-
formed in Medline and Medline In-Process bibliographic
databases using the clinicaltrials.gov identification num-
ber (clinical trial ID) or the manufacturer’s study ID. If
no full-text publication was identified in the biblio-
graphic databases, a search was performed in the registry
of clinical studies clinicaltrial.gov. Finally, a study synop-
sis or summary was retrieved from the manufacturers’
websites. Only prospective phase III clinical trials of
insulin analogs that reported clinical outcomes were
included, as insulin analogs (in comparison with human
insulin) are more recently available and have followed
the most recent regulatory procedures.
Data collected included country of origin, design of
the study, sample size, mean age, type of diabetes, dur-
ation of diabetes, proportion of males, use of insulin be-
fore enrollment into study, target glycated hemoglobin
(HbA1c) in the inclusion and exclusion criteria, mean
HbA1c, use and purpose of BG measurement, method
of insulin dose adjustment, structuration of SMBG,
provision of education/training for SMBG, and monitor-
ing of compliance in SMBG. The data were extracted by
one reviewer and validated by a second reviewer. Any
disagreements were resolved by consensus. No statistical
hypothesis was tested. The main outcomes included
frequency of use of BG monitoring and use of BG
monitoring for insulin dose adjustment. Summary
statistics were provided using SPSS version 20 (IBM
Corp., Armonk, New York, USA). Study did not require
ethical approval, as it did not include any patient’s data.
Results
Clinical studies search
Altogether 46 phase III clinical trials were identified in
the manufacturers’ websites. One retrospective study
(NCT00410033) was excluded from analysis, as it did
not meet inclusion criteria. The database search in
Medline provided 27 full-text articles, one of which was
identified as a duplicate [15] and five as redundant pub-
lications [16–20]. All five redundant publications were
considered less informative than the main published
phase III clinical study in question. EMA provided eight
out of the 45 requested extracts of Clinical Study
Reports of the phase III insulin analog studies. The
majority of the Clinical Study Reports were not held by
EMA. The analog reports which were provided consisted
of the following: insulin glulisine (n = 1), biphasic insulin
aspart (n = 3) and insulin lispro (n = 4). For three studies,
both the Clinical Study Reports and full-text publications
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were available, but for five studies, only the Clinical Study
Report was available. A detailed description of the
selection process as adapted from the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) framework [21] is presented in Fig. 1.
Description of included studies
The characteristics of the included studies are de-
scribed in Table 1. Of the identified phase III studies,
62 % (n = 28) were rapid-acting insulin analog studies
and 38 % (n = 17) were pre-mixed insulin analog studies.
Of the rapid-acting analogs, 29 % (n = 8) were insulin
aspart, 57 % (n = 16) were insulin glulisine and 14 % (n = 4)
were insulin lispro. Of the pre-mixed insulin analog
studies, 71 % (n = 12) were biphasic insulin aspart studies
and 29 % (n = 5) insulin lispro mix studies.
The majority (n = 40, 89 %) of the included studies
were RCTs. In total 60 % (n = 27) were single-country
studies conducted in USA (n = 9, 20 %), Japan (n = 5,
11 %), China (n = 3, 7 %), Russia (n = 2, 5 %), and 1
(n = 1, 2 %) each in Germany, Denmark, Italy, France,
Mexico, the Netherlands and Ukraine. There were
29 % (n = 13) of the studies conducted in multiple
countries; the location was not specified in 14 % (n = 6) of
the studies. The median number of patients in the studies
was 280 (interquartile range 113–403).
Type 1 diabetes mellitus (DM) patients were included
in 31 % (n = 14) and type 2 DM patients in 51 % (n = 23)
of the studies. A mixed population consisting of patients
with both type 1 and 2 DM was identified in 16 % (n = 7)
of the studies. One study included patients with gesta-
tional DM only.
Fig. 1 Selection of phase III trials and subsequent full-text publications (adapted from PRISMA [21])
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Table 1 Characteristics of the included study reports
Insulin analog type Insulin analog Clinical trial ID EMA report First author of
full-text article
Year Design Sample size Mean age
of total
Population DM type Mean duration
of DM in years




NCT01388361 N Mathieu [29] 2014 RCT 413 61.3 A II 11.8 64 7.3
NCT00097071 N Weinzimer [30] 2008 RCT 299 13.1 C I 6.1 48 8.1
NCT00604656 N None 2004 RCT 241 40.2 A I 13.6 66 7.8
NCT00071448 N None 2006 RCT 378 11.6 C I 4.6 52 8.3
NCT01486940 N Hermansen [27] 2004 RCT 644 39.1 A I 15.2 63 8.4
NCT00065130 N Pettitt [31] 2007 RCT 27 30.7 A GDM – 0 5.2
NCT00832182 N None [32]* 2002 Cohort 75 – A I – – –
NCT01707134 N Home [33] 2006 RCT 753 38.8 A I 15.2 58 –
Insulin glulisine
(Apidra)
NCT00467376 N None 2009 RCT 484 – A I, II 10.3 – 8.6
NCT00115570 N None 2009 RCT 572 12.5 C I – – –
NCT00290979 N None 2006 RCT 267 – A I – – –
NCT00290927 N None 2005 RCT 393 – A II – – –
NCT00135057 Y Bergenstal [34] 2008 RCT 270 55.1 A II 13.0 44 8.2
NCT00135096 N Ratner [35] 2011 RCT 716 53.8 A II 14.0 44 8.4
NCT00174668 N None 2008 RCT 310 – A II – – –
NCT00546702 N None 2005 CS 140 – A I – – –
NCT00545337 N None 2007 CS 60 34.7 A I 12.7 45 –
NCT00174642 N None 2009 RCT 464 58.5 A II – 45 9.1
NCT00272012 N None 2007 RCT 393 – A II – – –
NCT00135941 N Testa [36] 2012 RCT 388 54.0 A I, II 16.1 47 7.8
NCT00135083 N Davidson [37] 2011 RCT 343 – A II – 5 –
NCT00272064 N Del Prato [38] 2012 RCT 241 58.3 A II 10.9 52 8.9
NCT00271284 N Renard [39] 2011 RCT 135 46.8 A I 18 61 7.1
NCT00397553 N None 2009 CS 104 35.0 A I 25.3 – 8.8
Insulin lispro
(Humalog)
F3Z-MC-IOAE Y None 1994 RCT 98 24.4 M I 0.2 61 –
F3Z-MC-IOAF Y None 1994 RCT 377 56.1 A II 7.8 56 –
F3Z-MC-IOAG Y None 1993 RCT 1037 33.4 M I 12.1 58 8.5














Table 1 Characteristics of the included study reports (Continued)
Pre-mixed Biphasic insulin aspart
(Novo Mix)
NCT00476437 N None 2008 RCT 81 62.3 A II 18.3 54 7.8
NCT00318786 N Kadowaki [40] 2010 RCT 289 62.5 A II 15.7 59 8.5
NCT00313001 N None 2007 RCT 372 52.6 A II – 48 10.2
NCT00184574 N Cucinotta [41] 2009 RCT 603 60.5 A II – 44 8.9
NCT00097877 N Bergenstal [42] 2009 RCT 372 52.6 A II – 48 10.2
NCT00184600 N Holman [18] 2009 RCT 708 61.7 A II 9 64 8.5
NCT00097279 Y Raskin [43] 2007 RCT 230 53.8 A II 8.8 42 8.1
NCT00564668 N None 2005 RCT 126 62.2 A II 16.4 62 7.2
NCT00612599 N Parkner [44] 2010 RCT 75 60.4 A II 11.7 70 7.5
NCT00617565 Y None 2004 RCT 219 55.8 A I, II 11.1 56 8.8
NCT01467375 N None [45]* 2005 CS 89 65.1 A II 15.2 65 8.1
NCT01467323 Y Boehm [46] 2002 RCT 294 54.0 A I, II 15.3 58 8.3
Insulin lispro mix
(Humalog Mix)
NCT00191581 N Gao [47] 2008 RCT 120 55.7 A I, II 11.4 40 8.1
NCT00551356 N None 2003 RCT 53 50.4 A II 6.5 57 –
F3Z-JE-IOMO N None 2003 RCT 215 55.9 A I, II 15.0 58 –
F3Z-MC-IONA N None 2006 RCT 106 52.4 A I, II 10.4 52 –
NCT00036504 N None 2007 RCT 105 54.9 A II 8.9 62 8.6
Abbreviations: EMA European Medicines Agency; design: RCT randomized control trial, CS case series study; population: A adult, C child and/or adolescent, M mixed
DM diabetes mellitus; type: I diabetes mellitus type I, II–diabetes mellitus type II, GDM-gestational diabetes; HbA1c-glycated hemoglobin














In 89 % (n = 40) of the studies, only adults were
included, and in 7 % (n = 3) only children and/or adoles-
cents were included. In two (4 %) studies, the patient
population was mixed where both adults and children
were included. Mean age of patients in all studies was
48.3 (standard deviation [SD] 14.6) years. Males consti-
tuted on average 53 % of all study participants. The
mean duration of diabetes prior to enrolment was 12.2
(SD 4.6) years and insulin therapy had been initiated
prior to enrolment in 78 % of the studies. Patients had
not received insulin therapy prior to enrolment in 13 %
of the studies. The mean level of HbA1c at baseline was
8.3 % (SD 0.9 %).
BG monitoring in the included studies
BG monitoring
A summary of the results is presented in Table 2.
Regular monitoring of BG was reported in 100 % (n = 45)
of the studies as shown in Fig. 2.
Insulin doses were reportedly adjusted based on
regular BG measurements in 91 % of phase III studies
(Fig. 3). In total 31.1 % the studies were with patients
making insulin dose adjustments using BG values.
Physician-adjusted insulin dosing using BG values was
reported in 37.8 % of the clinical studies that reported
BG monitoring. In 4.4 % of the studies dose adjustment
was reported by both patients and physicians. In 18 % of
the studies, dose adjustment based on BG values was
performed, but it was not specified by whom.
SMBG monitoring
SMBG was reported in 93 % (n = 42) of the phase III
clinical studies. The proportions of studies using either
rapid-acting or pre-mixed insulin analogs were similar in
terms of those reporting SMBG. SMBG was used as the
only means of BG monitoring in 84 % (n = 38) of the
studies. Monitoring of BG using only laboratory means
was reported in 7 % (n = 3) of the studies. Both
laboratory and SMBG measurements were reported in
9 % (n = 4) of the studies.
With regard to insulin dose adjustments based on
SMBG, 33.3 % (n = 14) of the phase III clinical studies
reported that patients self-adjusted insulin doses based
on SMBG results. The proportion of these studies using
either rapid-acting (n = 9, 34.6 %) or pre-mixed insulin
(n = 5, 31.3 %) was the same. Adjustment of insulin
doses by physicians based on SMBG values were re-
ported in 38.1 % (n = 16) of the studies. Dose adjustment
by physicians based on SMBG was similar in the pre-
mixed (n = 6, 37.5 %) and the rapid-acting insulin analog
(n = 10, 38.5 %) studies. In two studies (4.8 %) SMBG-
based dose adjustments were reported both by patients
and physicians. In four (9.5 %) studies that reported dose
adjustments based on SMBG, it could not be determined
whether the dose adjustments were carried out by
physician or patient.
Daily frequencies of SMBG measurement were
reported in 83 % (n = 35) of the studies that reported the
use of SMBG. In general, the daily frequencies varied
between one to nine tests.
Training, education and provision of instructions for
the proper use of SMBG were reported in 55 % (n = 23)
of the phase III studies where SMBG was reported.
Monitoring the proper use of SMBG was reported in 64 %
(n = 27) of the studies that reported SMBG measurements.
The monitoring was frequently done by regular checks via
telephone and by inspecting patient diaries.
Discussion
To our knowledge, the present study is the first to sys-
tematically assess the role of SMBG in phase III clinical
studies. It confirms the role of BG measurement as an
essential component of safe and effective insulin therapy.
We found that in 100 % of phase-III clinical studies of
analog insulins, BG monitoring was regularly used.
SMBG was the most prevalent monitoring option and
was reported in 93 % of the studies.
We also found that in the majority of the studies
insulin therapy was regularly adjusted based on the BG
measurements. Therefore, the safety and efficacy of insu-
lin use requires guidance for patients in the use of BG
measurements and the corresponding dose adjustments.
Of the studies reporting BG use, 31 % included insulin
dose self-adjustment by patients, 38 % with dose adjust-
ment by physicians, 4 % with dose adjustment by both
patients and physicians and finally 18 % in which dose
adjustment was performed, but it was not reported by
whom. For the other studies that did not explicitly men-
tion insulin dose adjustment based on BG measurement,
we cannot rule out that dose adjustment did not occur.
However, all these studies were unpublished and no
Clinical Study Reports were available. If the analysis is
limited only to the studies for which either full text
publication or the Clinical Study Report is available, then
insulin dose adjustment based on BG measurements
would be in 100 % of the studies, both for rapid-acting
and pre-mixed insulins.
Our analysis also showed that only 55 % of the exam-
ined studies report that training, education or provision
of instructions about the use of SMBG took place. We
believe that this relatively low value reflects incomplete
reporting in the studies, rather than a lack of provision
of training. Studies have demonstrated that structured
testing can enhance the value of SMBG [22–24].
Structured testing means measuring BG at specific times
or in relation to activities in order to best evaluate the
effect of therapy, diet and physical activity on the BG
level [25]. In a review of the European Public
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Table 2 Review of phase III insulin analog clinical trials











Rapid-acting Pre-mix All insulin
analog studies
Total number of trials (n) 8 16 4 12 5 28 17 45
All insulin analog studies (n = 45)
Proportion of trials reporting BG measurement (%) 100 % 100 % 100 % 100 % 100 % 100 % 100 % 100 %
Reported BG by SMBG, laboratory or both (n = 45)
Reported BG measurement by SMBG only (%) 100 % 82 % 75 % 83 % 80 % 86 % 82 % 84 %
Reported BG measurement by laboratory measurement only (%) 0 % 12 % 0 % 0 % 20 % 7 % 6 % 7 %
Reported BG by both SMBG and laboratory measurements (%) 0 % 6 % 25 % 17 % 0 % 7 % 12 % 9 %
Reported regular insulin dose adjustments (using BG measurements, n = 45)
Reported dose adjustments according to BG measurement (%) 87.5 % 100 % 100 % 91.6 % 60.0 % 96.4 % 82.4 % 91.1 %
Reported regular dose adjustments by patient or physician (using BG
measurements, n = 45)
Reported dose adjustments by patient (%) 25.0 % 43.7% 0 % 41.7 % 0 % 32.1 % 29.4 % 31.1 %
Reported dose adjustments by physician (%) 37.5 % 25.0 % 100 % 33.3 % 40.0 % 39.3 % 35.3 % 37.8 %
Reported dose adjustments by patient and physician (%) 0 % 6.3 % 0 % 8.3 % 0 % 3.6 % 5.9 % 4.4 %
Reported dose adjustments, not specified by patient or physician (%) 25.0 % 25.0 % 0 % 8.3 % 20.0 % 21.4 % 11.8 % 17.8 %
Reported regular dose adjustments using SMBG measurements (n = 42)
Patient self-adjustments using SMBG values (%) 25.0 % 50 % 0 % 41.7 % 0 % 34.6 % 31.3 % 33.3 %
Physician adjustments using SMBG values (%) 37.5 % 28.6 % 75 % 33.3 % 50 % 38.5 % 37.5 % 38.1 %
Patient and physician adjustments using SMBG values (%) 0 % 7.1 % 0 % 8.3 % 0 % 3.8 % 6.3 % 4.8 %
Dose adjustments using SMBG mentioned but not specified whether by
patient or physician (%)














Assessment Reports for insulin analogs, it was revealed
that unspecific and unclear recommendations for BG
monitoring is occasionally provided [7]. To ensure safe
and effective use of insulin, manufacturers should be
encouraged to provide clearer recommendations for
patients and medical professionals.
This study contributes to the understanding of the
essential role of BG monitoring in insulin-dependent
diabetes. Insulin is safe and effective if used only in
combination with regular BG monitoring. This is true
for both rapid-acting and pre-mixed insulins, the latter
typically used in conventional insulin therapy. The value
of BG monitoring is for providing essential information
for making therapeutic choices, either by the patient or
the physician. And SMBG is only helpful, if it results in
therapeutic consequences. To achieve that SMBG shall
be placed in the center of the disease management for
diabetic patients, including appropriate training of struc-
tured testing, as mentioned above. The use of both
SMBG and insulin is funded in the majority of devel-
oped countries by payers. In some developing countries,
reimbursement is not available for BG meters and strips,
while coverage for insulin treatment is provided. The
lack of affordability or reimbursement limitations of
SMBG may impair adherence to the recommended BG
test frequencies and result in not achieving the required
level of efficacy and safety of insulin, which could
ultimately lead to adverse outcomes for the patients and
Fig. 2 Proportion of phase III clinical trials that reported regular BG monitoring per insulin analog type
Fig. 3 Proportion of phase III trials reporting insulin dose adjustments
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an increase in cost to the health care system due to
ineffective management of diabetes.
Data on the impact of non-provision of SMBG on
insulin-dependent patients are limited, although some
emerging evidence shows a potential serious risk of a re-
duction of insulin effectiveness. In China, where SMBG
is not reimbursed, a study in 2011 with 10,418 patients
with diabetes revealed that a high proportion of insulin-
dependent patients do not have a meter at home to per-
form SMBG (51.6 % of patients on intensive insulin
therapy, 46.6 % on conventional insulin therapy and
39.9 % on basal-supported oral therapy) [26]. In all three
of these clinical groups, the average level of HbA1c was
higher in patients who did not have access to a SMBG
meter (e.g., HbA1c 8.1 % with SMBG vs HbA1c 9.3 %
without SMBG among patients on intensive insulin
therapy). In another study from India (n = 2250) using a
similar study methodology as in the study in China of
accessibility to SMBG, it was found that 41.5 % of
patients on intensive insulin therapy, 54.3 % on conven-
tional insulin therapy and 44.6 % on basal-supported
oral therapy did not have a meter at home to perform
SMBG [27]. The level of glycemic control was lower in
patients who did not perform SMBG. In a study per-
formed in Italy, it was demonstrated that patients using
SMBG had a reduced risk of diabetes-related hospitaliza-
tions and consequently a lower overall total annual cost
per patient [28]. Total annual cost was €3060 in the
group of no SMBG users vs. €2738 in the group of
patients using SMBG, which was mainly explained by
statistically significant reduction of diabetes-related
hospitalizations.
Non-coverage of SMBG in some developing countries
is a good example of ‘silo budgeting’ to overcome, when
different payers are responsible for provision of drugs
and diagnostics/medical aids. Being disconnected, the
decision-making and financial flows for drugs and
medical aids may lead to a break in provision of strongly
co-dependent technologies, such as with insulin and
SMBG. Many countries have taken action to overcome
this hurdle, which requires a holistic view of the out-
comes and costs in health care from the perspective of
the entire society and not just from the perspective of a
single payer.
Our study has some limitations. First, our search for full
text articles was limited to one bibliographic database and
was performed using a clinical trial identifier, which may
have led to the loss of some relevant publications. Never-
theless, we were able to answer the primary question
about the use of BG monitoring from the studies
examined using a combination of sources, including full
text articles, study synopses and EMA reports. The non-
inclusion of existing full text reports may have potentially
led to underreporting of dose adjustment, based on
SMBG, and to the provision for training to patients on the
use of SMBG. Second, our study scope was only on regis-
tered phase III studies, which was used as a foundation for
insulin analog safety and efficacy claims and consequent
regulatory approval, and did not include other pre- and
post-marketing studies.
Conclusions
To conclude, the findings from this review endorse the
crucial role of BG measurement in general and of SMBG
specifically as a co-dependent intervention component
of insulin treatment. The majority of phase III registra-
tion studies reported on the use of BG measurements
for establishing safe and efficacious administration of in-
sulin. The indispensable role of SMBG in treatment for
insulin-dependent patients should receive the attention
of health care payers in order to consistently assess and
reimburse SMBG along with insulins to ensure the safety
and effectiveness of insulin treatment.
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